ARDS and corticosteroids: beyond COVID-19
Mariano Esperatti, Matías Olmos, Nora Fuentes · 2026
Read ARDS and corticosteroids: beyond COVID-19 by Mariano Esperatti, Matías Olmos, Nora Fuentes (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13200361.txt.
Description
Mariano Esperatti and colleagues review steroid use in acute respiratory distress syndrome in a 2026 article. ARDS is severe lung failure with high death rates. Inflammation drives the damage, so steroids, which calm inflammation, have long been a plausible therapy, yet practice still varies worldwide.
Trials over decades tested varied drugs, doses, and start times, with COVID-19 adding proof for virus-driven cases. A new wider definition now covers patients on noninvasive support, raising questions about older evidence. The authors propose a practical framework: start early, within one to two days, at solid doses for at least seven days, matched to cause and patient traits. Subtype-specific proof remains a research need.
Catalog record
| CREATOR | Mariano Esperatti, Matías Olmos, Nora Fuentes |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |